跳至主要内容
临床试验/NCT02275013
NCT02275013已完成不适用

Levosimendan Administration and Outcome in Cardiac Surgery

Charite University, Berlin, Germany1 个研究点 分布在 1 个国家目标入组 159 人开始时间: 2006年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
159
试验地点
1
主要终点
In-hospital mortality

研究概览

简要总结

To assess the effects on outcome of levosimendan with respect to timing of its administration on the postoperative course of high-risk cardiac surgery patients in a retrospective observational study.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients undergoing cardiac surgery between 2006 and 2013
  • levosimendan administration within 24 hours of postoperative ICU admission

排除标准

  • patients younger than 18

研究组 & 干预措施

Early

Levosimendan administration within first hour of post-operative ICU admission

干预措施: Levosimendan (Drug)

Late

Levosimendan administration within 24 hours of post-operative ICU admission but after first hour

干预措施: Levosimendan (Drug)

结局指标

主要结局

In-hospital mortality

时间窗: until discharge, an average of 3 weeks length of stay

1 year follow-up mortality

时间窗: 1 year after surgery

次要结局

  • Duration of mechanical ventilation(until discharge, an average of 3 weeks length of stay)
  • Incidence of renal dysfunction(until discharge, an average of 3 weeks length of stay)
  • Incidence of renal replacement therapy(until discharge, an average of 3 weeks length of stay)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael Sander

Univ-Prof. Dr. med.

Charite University, Berlin, Germany

研究点 (1)

Loading locations...

相似试验

Levosimendan Administration and Outcome in Cardiac... | 临床试验